Figure 4
From: MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
Midostaurin plus trametinib exert synergistic cytotoxicity in FLT3-WT AML samples in vitro and ex vivo. (a) Dose-response curve of trametinib and midostaurin in an FLT3-WT culture (OCI-AML3). (b) Normalized isobolograms for trametinib in combination with the TKI midostaurin in FLT3-WT OCI-AML3 cells. (c) Dose-response curve of midostaurin and trametinib in five ex vivo FLT3-WT AML samples. (d) Normalized isobolograms for trametinib in combination with the TKI midostaurin in five ex vivo FLT3-wildtype AML samples.
